Silencing of integrated human papillomavirus type 18 oncogene transcription in cells expressing SerpinB2

Journal of Virology

Volumn 79, Issue 7, 2005, Pages 4246-4256

  Darnell, Grant A ^a   Antalis, Toni M ^c   Rose, Barbara R ^b   Suhrbier, Andreas ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; LIVER ENRICHED TRANSCRIPTIONAL INHIBITORY PROTEIN; MYC PROTEIN; PROTEIN C JUN; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN; SERINE PROTEINASE INHIBITOR; SERPINB2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; GENE SILENCING; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; SQUAMOUS EPITHELIUM; TRANSCRIPTION REGULATION; UTERINE CERVIX CARCINOMA; VIRUS ONCOGENE;

BINDING SITES; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL TRANSFORMATION, VIRAL; DNA-BINDING PROTEINS; GENE SILENCING; HELA CELLS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MYC; RETINOBLASTOMA PROTEIN; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 15244361972     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.7.4246-4256.2005     Document Type: Article

References (61)

1. Antalis, T. M., M. La Linn, K. Donnan, L. Mateo, J. Gardner, J. L. Dickinson, K. Buttigieg, and A. Suhrbier. 1998. The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming. J. Exp. Med. 187:1799-1811.
2. Badal, S., V. Badal, I. E. Calleja-Macias, M. Kalantari, L. S. Chuang, B. F. Li, and H. U. Bernard. 2004. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 324:483-492.
3. Bauknecht, T., P. Angel, H. D. Rover, and H. zur Hausen. 1992. Identification of a negative regulatory domain in the human papillomavirus type 18 promoter: interaction with the transcriptional represser YY1. EMBO J. 11:4607-4617.
4. Bauknecht, T., F. Jundt, I. Herr, T. Oehler, H. Delius, Y. Shi, P. Angel, and H. Zur Hausen. 1995. A switch region determines the cell type-specific positive or negative action of YY1 on the activity of the human papillomavirus type 18 promoter. J. Virol. 69:1-12.
5. Bauknecht, T., R. H. See, and Y. Shi. 1996. A novel C/EBP β-YY1 complex controls the cell-type-specific activity of the human papillomavirus type 18 upstream regulatory region. J. Virol. 70:7695-7705.
6. Bauknecht, T., and Y. Shi. 1998. Overexpression of C/EBPβ represses human papillomavirus type 18 upstream regulatory region activity in HeLa cells by interfering with the binding of TATA-binding protein. J. Virol. 72:2113-2124.
7. Bednarek, P. H., B. J. Lee, S. Gandhi, E. Lee, and B. Phillips. 1998. Novel binding sites for regulatory factors in the human papillomavirus type 18 enhancer and promoter identified by in vivo footprinting. J. Virol. 72:708-716.
8. Bird, C. H., E. J. Blink, C. E. Hirst, M. S. Buzza, P. M. Steele, J. Sun, D. A. Jans, and P. I. Bird. 2001. Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1. Mol. Cell. Biol. 21:5396-5407.
9. Chakrabarti, O., and S. Krishna. 2003. Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression. J. Biosci. 28:337-348.
10. Chang, Y. E., and L. A. Laimins. 2000. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74:4174-4182.
11. Charles, A., X. Tang, E. Crouch, J. S. Brody, and Z. X. Xiao. 2001. Retinoblastoma protein complexes with C/EBP proteins and activates C/EBP-mediated transcription. J. Cell. Biochem. 83:414-425.
12. Chau, B. N., H. L. Borges, T. T. Chen, A. Masselli, I. C. Hunton, and J. Y. Wang. 2002. Signal-dependent protection from apoptosis in mice expressing caspase-resistant Rb. Nat. Cell Biol. 4:757-765.
13. Chen, P. L., D. J. Riley, S. Chen-Kiang, and W. H. Lee. 1996. Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. Proc. Natl. Acad. Sci. USA 93:465-469.
14. Daneri-Navarro, A., G. Macias-Lopez, A. Oceguera-Villanueva, S. Del Toro-Arreola, A. Bravo-Cuellar, R. Perez-Montfort, and S. Orbach-Arbouys. 1998. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur. J. Cancer 34:566-569.
15. Darnell, G. A., T. M. Antalis, R. W. Johnstone, B. W. Stringer, S. M. Ogbourne, D. Harrich, and A. Suhrbier. 2003. Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol. Cell. Biol. 23:6520-6532.
16. Dell, G., and K. Gaston. 2001. Human papillomaviruses and their role in cervical cancer. Cell. Mol. Life Sci. 58:1923-1942.
17. Descombes, P., and U. Schibler. 1991. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 67:569-579.
18. Dickinson, J. L., E. J. Bates, A. Ferrante, and T. M. Antalis. 1995. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J. Biol. Chem. 270:27894-27904.
19. Dickinson, J. L., B. J. Norris, P. H. Jensen, and T. M. Antalis. 1998. The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis. Cell Death Differ. 5:163-171.
20. Foekens, J. A., F. Buessecker, H. A. Peters, U. Krainick, W. L. van Putten, M. P. Look, J. G. Klijn, and M. D. Kramer. 1995. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res. 55:1423-1427.
21. Gohl, G., T. Lehmkoster, P. A. Munzel, D. Schrenk, R. Viebahn, and K. W. Bock. 1996. TCDD-inducible plasminogen activator inhibitor type 2 (PAI-2) in human hepatocytes, HepG2 and monocytic U937 cells. Carcinogenesis 17:443-449.
22. Hadaschik, D., K. Hinterkeuser, M. Oldak, H. J. Pfister, and S. Smola-Hess. 2003. The papillomavirus E2 protein binds to and synergizes with C/EBP factors involved in keratinocyte differentiation. J. Virol. 77:5253-5265.
23. Harbour, J. W., and D. C. Dean. 2000. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14:2393-2409.
24. Harima, Y., S. Sawada, K. Nagata, M. Sougawa, and T. Ohnishi. 2001. Chromosome 6p21.2, 18q21.2 and human papilloma virus (HPV) DNA can predict prognosis of cervical cancer after radiotherapy. Int. J. Cancer 96: 286-296.
25. Hasina, R., K. Hulett, S. Bicciato, C. Di Bello, G. J. Petruzzelli, and M. W. Lingen. 2003. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res. 63:555-559.
26. Hattori, T., N. Ohoka, H. Hayashi, and K. Onozaki. 2003. C/EBP homologous protein (CHOP) up-regulates IL-6 transcription by trapping negative regulating NF-IL6 isoform. FEBS Lett. 541:33-39.
27. Irving, J. A., S. S. Shusbanov, R. N. Pike, E. Y. Popova, D. Bromme, T. H. Coetzer, S. P. Bottomley, I. A. Boulynko, S. A. Grigoryev, and J. C. Whisstock. 2002. Inhibitory activity of a heterochromatin-associated serpin (MENT) against papain-like cysteine proteinases affects chromatin structure and blocks cell proliferation. J. Biol. Chem. 277:13192-13201.
28. Jang, J. S., S. J. Lee, Y. H. Choi, P. M. Nguyen, J. Lee, S. G. Hwang, M. L. Wu, E. Takano, M. Maki, P. A. Henkart, and J. B. Trepel. 1999. Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease. Oncogene 18:1789-1796.
29. Jensen, P. J., Q. Wu, P. Janowitz, Y. Ando, and N. M. Schechter. 1995. Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope. Exp. Cell Res. 217:65-71.
30. Jover, R., R. Bort, M. J. Gomez-Lechon, and J. V. Castell. 2002. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 16:1799-1801.
31. Kruithof, E. K., M. S. Baker, and C. L. Bunn. 1995. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86:4007-4024.
32. Kuang, P. P., and R. H. Goldstein. 2003. Regulation of elastin gene transcription by interleukin-1 beta-induced C/EBP beta isoforms. Am. J. Physiol. Cell Physiol. 285:C1349-C1355.
33. Lian, X., and T. Yang. 2004. Plasminogen activator inhibitor 2: expression and role in differentiation of epidermal keratinocyte. Biol. Cell. 96:109-116.
34. Lipinski, M. M., and T. Jacks. 1999. The retinoblastoma gene family in differentiation and development. Oncogene 18:7873-7882.
35. Lyons-Giordano, B., D. Loskutoff, C. S. Chen, G. Lazarus, M. Keeton, and P. J. Jensen. 1994. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry 101:105-112.
36. McMurray, H. R., D. Nguyen, T. F. Westbrook, and D. J. McAnce. 2001. Biology of human papillomaviruses. Int. J. Exp. Pathol. 82:15-33.
37. Morris, E. J., and N. J. Dyson. 2001. Retinoblastoma protein partners. Adv. Cancer Res. 82:1-54.
38. Nakamura, M., H. Konno, T. Tanaka, Y. Maruo, N. Nishino, K. Aoki, S. Baba, S. Sakaguchi, Y. Takada, and A. Takada. 1992. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb. Res. 65:709-719.
39. O'Connor, M. J., W. Stunkel, C. H. Koh, H. Zimmermann, and H. U. Bernard. 2000. The differentiation-specific factor CDP/Cut represses transcription and replication of human papillomaviruses through a conserved silencing element. J. Virol. 74:401-410.
40. Petkova, V., M. J. Romanowski, I. Sulijoadikusumo, D. Rohne, P. Kang, T. Shenk, and A. Usheva. 2001. Interaction between YY1 and the retinoblastoma protein. Regulation of cell cycle progression in differentiated cells. J. Biol. Chem. 276:7932-7936.
41. Praus, M., K. Wauterickx, D. Collen, and R. D. Gerard. 1999. Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther. 6:227-236.
42. Psyrri, A., R. A. DeFilippis, A. P. Edwards, K. E. Yates, L. Manuelidis, and D. DiMaio. 2004. Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells. Cancer Res. 64:3079-3086.
43. Risse, B. C., H. Brown, R. M. Lavker, J. M. Pearson, M. S. Baker, D. Ginsburg, and P. J. Jensen. 1998. Differentiating cells of murine stratified squamous epithelia constitutively express plasminogen activator inhibitor type 2 (PAI-2). Histochem. Cell Biol. 110:559-569.
44. Rose, B., G. Steger, X. P. Dong, C. Thompson, Y. Cossart, M. Tattersall, and H. Pfister. 1998. Point mutations in SP1 motifs in the upstream regulatory region of human papillomavirus type 18 isolates from cervical cancers increase promoter activity. J. Gen. Virol. 79:1659-1663.
45. Ruiz, S., M. Santos, C. Segrelles, H. Leis, J. L. Jorcano, A. Berns, J. M. Paramio, and M. Vooijs. 2004. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 131:2737-2748.
46. Ruutu, M., P. Peitsaro, B. Johansson, and S. Syrjanen. 2002. Transcriptional profiling of a human papillomavirus 33-positive squamous epithelial cell line which acquired a selective growth advantage after viral integration. Int. J. Cancer 100:318-326.
47. Salcedo, M., E. Garrido, L. Taja, and P. Gariglio. 1995. The retinoblastoma gene product negatively regulates cellular or viral oncogene promoters in vivo. Arch. Med. Res. 26:5157-5162.
48. Shafren, D. R., J. Gardner, V. H. Mann, T. M. Antalis, and A. Suhrbier. 1999. Picornavirus receptor down-regulation by plasminogen activator inhibitor type 2. J. Virol. 73:7193-7198.
49. Silverman, G. A., P. I. Bird, R. W. Carrell, F. C. Church, P. B. Coughlin, P. G. Gettins, J. A. Irving, D. A. Lomas, C. J. Luke, R. W. Moyer, P. A. Pemberton, E. Remold-O'Donnell, G. S. Salvesen, J. Travis, and J. C. Whisstock. 2001. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276:33293-33296.
50. Steenbergen, R. D., M. A. Hermsen, J. M. Walboomers, H. Joenje, F. Arwert, C. J. Meijer, and P. J. Snijders. 1995. Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line. Cancer Res. 55:5465-5471.
51. Struyk, L., E. van der Meijden, R. Minnaar, V. Fontaine, I. Meijer, and J. ter Schegget. 2000. Transcriptional regulation of human papillomavirus type 16 LCR by different C/EBPβ isoforms. Mol. Carcinog. 28:42-50.
52. Su, W. C., H. Y. Chou, C. J. Chang, Y. M. Lee, W. H. Chen, K. H. Huang, M. Y. Lee, and S. C. Lee. 2003. Differential activation of a C/EBP beta isoform by a novel redox switch may confer the lipopolysaccharide-inducible expression of interleukin-6 gene. J. Biol. Chem. 278:51150-51158.
53. Wells, S. I., B. J. Aronow, T. M. Wise, S. S. Williams, J. A. Couget, and P. M. Howley. 2003. Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer cells. Proc. Natl. Acad. Sci. USA 100:7093-7098.
54. Welm, A. L., N. A. Timchenko, and G. J. Darlington. 1999. C/EBPα regulates generation of C/EBPβ isoforms through activation of specific proteolytic cleavage. Mol. Cell. Biol. 19:1695-1704.
55. Xiong, W., C. C. Hsieh, A. J. Kurtz, J. P. Rabek, and J. Papaconstantinou. 2001. Regulation of CCAAT/enhancer-binding protein-beta isoform synthesis by alternative translational initiation at multiple AUG start sites. Nucleic Acids Res. 29:3087-3098.
56. Yoshino, H., Y. Endo, Y. Watanabe, and T. Sasaki. 1998. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br. J. Cancer 78:833-839.
57. Yu, H., F. Maurer, and R. L. Medcalf. 2002. Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood 99:2810-2818.
58. Zahnow, C. A., P. Younes, R. Laucirica, and J. M. Rosen. 1997. Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J. Natl. Cancer Inst. 89:1887-1891.
59. Zhang, M., G. Stevens, and M. C. Madigan. 2001. In vitro effects of radiation on human retinoblastoma cells. Int. J. Cancer 96(Suppl.):7-14.
60. Zhao, M., and X. X. Wu. 2002. [Analysis of genetic instabilities on chromosome loci 3, 6, 11, and 18 in human cervical carcinoma.] Ai Zheng 21:640-643.
61. Zhou, H. M., I. Bolon, A. Nichols, A. Wohlwend, and J. D. Vassalli. 2001. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. Cancer Res. 61:970-976.